BeiGene, Ltd.
06160
2022 9 30
13.09
571 XIVA
2022 9 30
2022 9 30
2022 2022
2023
(John V. Oyler)
55
(CLL)
2022
1
(Julia Wang)
29 9,000
10
2022
2022 9 30
51 2021 12 31 66
2022 9 30 5.619
5.576 8,800
8,370 2022 9 30 1.256
1.087
1.202 2022 9 30
6,270
2022 9 30 3.876 2021
2.064
2022 9 30 3.495 2021
1.925
2022
1.555
6,580
2022
1.282
7,700
2022 2,750
2,080
2022 1
2022
2,240 2,600
2
2022 9 30 3,810
2021
6.5
2021 3
2021 9 30 1,400
2022 9 30 8.260 2021
6.688
2022 9 30 7,650 2021
4,740
2021 8
2022 1
2022 9 30 4.264 2021
3.519
2022
2021
2,000 0
2022 9 30
3,640 2021 3,170
(SG&A) 2022 9 30 SG&A
3.229 2021 2.692 SG&A
SG&A
SG&A 2022 2021 SG&A
4,180 3,540
2022 9 30 2,400
4.384 5.2% 2021 4.623
2022 9 30 5.576
0.41 (ADS) 5.39 2021
4.381 0.36 ADS 4.72
1.256
3
2022 82%
2022
1.555
136%
2022 1.081
221%
(MCL)
(WM) (MZL)
2022
3,950 23% BTK
2022
1.282
67%
(NICE)
WM
NICE WM
(BTK)
BTK
58
25
4,700
3 ALPINE (IRC)
(PFS)
(MZL)
MZL BTK
4
(EMA) (CHMP)
(CLL)
10
IgG4 PD-1
Fcγ
9
30 11,500
(NMPA) (CDE)
(ESCC) (sBLA)
(NSCLC)
(Medsafe)
(MFDS)
3 RATIONALE 301
(HCC)
2022 (ESMO 2022)
ESMO 2022
NSCLC 3
RATIONALE 303
2022 (WCLC 2022)
NSCLC 3
RATIONALE 303(NCT03358875)
5
(BGB-A1217) Fc TIGIT
25 1,500
WCLC 2022
PD-L1 NSCLC 1
(NCT04047862)
ESMO 2022
NSCLC 1
BGB-11417 BCL-2
BGB-11417 10
300
2 (NCT05471843)
BCL-2 BGB-11417
2 BGB-11417-202 BGB-11417
R/R CLL/SLL
BGB-B167 1 (NCT05494762) BGB-B167
CEAx4-1BB
CEA (CRC)
TIM3 surzebiclimab(BGB-A425)
NSCLC
(HNSCC) (NCT03744468)
6
BGB-A445 OX40
NSCLC HNSCC
BGB-15025
1(HPK1)
BGB-16673 (CDAC) BTK
B
BGB-24714 (SMAC)
BGB-10188
PI3Kδ
BGB-23339 2(TYK2)
LAG3 LBL-007
900-102 (NCT03744468)
100 9.3
52,000 6
2023
10
16,000 2022 GMP
54,000 2023
10,000
7
McKesson Ontada Ontada
(RWE)
FDA CLL (SLL) (sNDA)
(PDUFA) FDA
2023 1
EMA CLL
CLL sNDA
NMPA CLL/SLL sNDA
(MHRA)
(Swissmedic) MZL CLL
3 ALPINE (NCT03734016)
64 (ASH)
MZL MAGNOLIA
B
12 10 14
8
NMPA
PD-L1
(ESCC)
(BLA)
sBLA NMPA
TGA
Medsafe
NSCLC ESCC
BLA MFDS
ESCC BLA
– FDA
ESCC BLA
– EMA
NSCLC ESCC
– MHRA (Reliance route)
NSCLC ESCC
–
ESCC
2023 FDA
ESCC HCC
BGB-11417 BCL-2
2022 ASH (NHL) CLL
(AML) (MM) 1 NCT04883957
NCT04277637 NCT04771130 NCT04973605
9
Zymeworks 2022 zanidatamab
HER2 2b (NCT04466891)
2022 2021
9 30 12 31 1
$ 5,072,510 $ 6,624,849
189,170 483,113
290,911 242,626
681,914 587,605
6,726,013 8,535,525
252,071 262,400
410,255 558,055
294,883 407,703
319,973 390,362
649,333 629,678
2,070,842 2,402,962
$ 4,655,171 $ 6,132,563
10
ADS ADS
9 30 3 9 30 9
2022 20211 20221 20211
$ 349,506 $ 192,461 $ 915,590 $ 437,202
38,122 13,979 120,236 525,102
387,628 206,440 1,035,826 962,304
76,543 47,413 212,953 116,361
426,363 351,937 1,194,485 1,028,754
322,892 269,227 948,868 683,622
187 188 563 563
825,985 668,765 2,356,869 1,829,300
(438,357) (462,325) (1,321,043) (866,996)
12,759 (2,230) 34,261 (11,275)
(125,640) 31,477 (243,290) 26,487
(551,238) (433,078) (1,530,072) (851,784)
6,318 5,036 28,408 15,354
(557,556) (438,114) (1,558,480) (867,138)
$ (0.41) $(0.36) $ (1.16) $ (0.72)
1,345,303,747 1,205,971,284 1,337,976,853 1,196,391,201
ADS
$ (5.39) $ (4.72) $ (15.14) $ (9.42)
ADS
103,484,904 92,767,022 102,921,296 92,030,092
11
1
2022 2021
2022 9 30 10-Q
1. 2.
740 (ASC 740)
12 (IAS 12)
2022
2022 10
2022 9 30
2022 9 30
2022 2021
2022
2021
ADS
2022 9
30 10-Q 2.
12
2021 12 31
110,424 (110,424) –
1,032,069 (110,424) 921,645
8,645,949 (110,424) 8,535,525
(4,966,103) (110,424) (5,076,527)
6,242,987 (110,424) 6,132,563
8,645,949 (110,424) 8,535,525
2021 9 30 2021 9 30
(19,223) 24,259 5,036 (24,083) 39,437 15,354
(413,855) (24,259) (438,114) (827,701) (39,437) (867,138)
(0.34) (0.02) (0.36) (0.69) (0.03) (0.72)
ADS (4.46) (0.26) (4.72) (8.99) (0.43) (9.42)
2022 9 30 2022 9 30
1,000
13
9,000
http://www.beigene.com.cn
Pharmacyclics
1995 (Private Securities Litigation
Reform Act of 1995)
CLL
Ontada
10-Q
14
2022 11 9
Anthony C. Hooper Margaret Han Dugan
Donald W. Glazer Michael Goller Ranjeev Krishana Thomas
Malley Alessandro Riva Corazon (Corsee) D. Sanders
15